2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds

Patent metadata

Field	Value
Publication number	US-12054510-B2
Application number	US-202217833780-A
Country	US
Kind code	B2
Filing date	Jun 6, 2022
Priority date	Nov 28, 2014
Publication date	Aug 6, 2024
Grant date	Aug 6, 2024

Abstract

The present invention relates to chemical compounds, the compounds for use in a method of treatment, particularly in a method of prophylaxis or treatment for cancer, a process for preparation of the compounds and pharmaceutical compositions comprising the compounds. The compounds may, in particular, be useful in the treatment of leukaemia, lymphoma and/or solid tumours in Homo sapiens. The compounds are derivatives of cordycepin (3′-deoxyadenosine).

First claim

The invention claimed is:

1. A compound which is 3′-Deoxyadenosine-5′-O-[phenyl(benzyloxy-L-alaninyl)] phosphate:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition, comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

3. The pharmaceutical composition of claim 2 , in an oral dosage form.

4. The pharmaceutical composition of claim 2 , in a liquid dosage form.

5. The pharmaceutical composition of claim 4 , in an aqueous solution of or suspension.

6. The pharmaceutical composition of claim 5 , in an intravenous formulation.

7. The pharmaceutical composition of claim 5 , in a parenteral formulation.

8. The pharmaceutical composition of claim 2 , that contains from 50 mg to 700 mg of the compound.

Assignees

• NuCana plc

Inventors

• Griffith Hugh
• Mcguigan Christopher
• Ferrari Valentina
• Serpi Michaela
• Antunez Carmen Jimenez

Classifications

• C07H19/173 Primary

  with 2-deoxyribosyl as the saccharide radical · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• A61K31/7076

  containing purines, e.g. adenosine, adenylic acid · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title